TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04143347

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Study: NCT00633035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole 40 mg
Description: esomeprazole 40 mg po given for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: famotidine 20 mg
Description: famotidine 20 mg intravenous bolus q12h for 7 days
Study: NCT00048724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (SCH 54031)
Description: 0.5 µg/kg subcutaneously once weekly for 60 months
Study: NCT04377516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training
Description: pelvic floor muscle training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle combined global muscle exercise training
Description: pelvic floor muscle combined global muscle exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle combined global muscle exercise training
Description: pelvic floor muscle combined global muscle exercise training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: education of pelvic girdle
Description: education of pelvic girdle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education of pelvic girdle
Description: education of pelvic girdle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: education of pelvic girdle
Description: education of pelvic girdle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education of pelvic girdle
Description: education of pelvic girdle
Study: NCT01867684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Study: NCT03603964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Guadecitabine
Study: NCT01943370

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early saline irrigation
Description: Initiation of post-operative saline irrigation earlier during the post-operative course

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Irrigation
Description: Routine initiation of saline irrigation
Study: NCT01148810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03722875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib is a selective VEGFR2 inhibitor
Study: NCT01672125

Intervention type: OTHER
Intervention: circumferential measurements in different upper limb positions.
Description: circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position

Intervention type: OTHER
Intervention: circumferential measurements in different upper limb positions.
Description: circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position

Intervention type: OTHER
Intervention: circumferential measurements in different upper limb positions.
Description: circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
Study: NCT04928742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy (CBT)
Description: The 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
Study: NCT00403455

Intervention type: DRUG
Group type: OTHER
Intervention: Paroxetine
Description: SSRI
Study: NCT03865121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)
Description: Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
Study: NCT02595684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calcined magnesia capsules: one per day, at night, during 28 days.
Study: NCT02802553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Goggle
Description: Smart Goggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs. The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off. The Smart Goggles is a non-invasive imaging system that does not require contact with patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardio-Green
Description: Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Elite Imaging system
Description: Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quest near-infrared (NIR) Imaging system
Description: Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDE Imaging system
Description: Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma probe
Description: Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue Dyes
Description: Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
Study: NCT02996721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol) will be provided to participants of the study.
Study: NCT03771729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ 696
Description: LCZ696 200mg twice daily
Study: NCT05416619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REMO®
Description: The patients receive daily 1 hour of conventional therapy and 1 hour of treatment of REMO®, that is a wearable composed by 8 bipolar electrodes able to detect the surface electromyography of the forearm muscles. REMO® allows the control of a computer interface using the surface electromyography to execute sEMG-biofeedback exercises for hand rehabilitation. The movements required for hand rehabilitation are the following: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. The patients are clinically evaluated before and after the REMO® treatment.
Study: NCT00399438

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablets, Oral, once daily, 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: BMS-562086
Description: Tablets, Oral, once daily, 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: BMS-562086
Description: Tablets, Oral, once daily, 2 weeks
Study: NCT01306136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: 15 psychotherapy sessions focused on helping clients overcome avoidance behaviors and emotionally process trauma-related memories

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Per usual care, patients are referred to a mental health provider within the health care setting.
Study: NCT03732638

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rimegepant
Description: Rimegepant 75 mg tablet EOD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Rimegepant 75 mg tablet EOD
Study: NCT02466776

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable subcuticular suture
Description: Patients will receive absorbable subcuticular suture for skin closure at time of cesarean delivery (CD).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stainless steel staples
Description: Patients will receive stainless steel staples for skin closure at time of cesarean delivery (CD).
Study: NCT02553005

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study: NCT02092584

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: 4 cap 1 g Omega-3 per day for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 cap 1 g Placebo(paraffin) per day for 2 months
Study: NCT02866370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days\* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity.
Study: NCT03908996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Profile by Sanford weight management plan
Description: The purpose of this study is to observe weight changes in patients who completed endometrial cancer treatment, are clinically overweight, and who participate in the Profile by Sanford weight management program. An exploratory purpose is to examine the bacterial content of the patient's gut by examining stool specimens before starting the Profile by Sanford weight management program and after 6 months of participation in the Profile by Sanford weight management program.
Study: NCT03564119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S5G4T-1
Description: Once a day topical cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S5G4T-2
Description: Once a day topical cream
Study: NCT00564850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate 11.25mg (Decapeptyl® SR)
Description: One intra muscular injection at day 1 and month 3.
Study: NCT04812444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zylox Peripheral Venous Stent
Description: Self-expanding stent implantation during the index procedure.
Study: NCT02866370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity.
Study: NCT03732638

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet to match rimegepant tablet EOD
Study: NCT02543541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured palliative care
Description: Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
Study: NCT04812444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zilver Vena Venous Stent
Description: Self-expanding stent implantation during the index procedure.
Study: NCT04526015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iliohypogastric and ilioinguinal nerve block
Description: Each patient will receive spinal anesthesia plus bilateral ultrasound-guided IL/IH nerve block. The abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualized between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Controlled Group
Description: Each patient will receive spinal anesthesia alone with no block.
Study: NCT03214601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: penetrating atherosclerotic ulcer, aorta branch cardiovascular implant
Description: The Relay Branch System is intended to provide an option for patients with arch and proximal descending chronic thoracic aortic pathologies.
Study: NCT01252095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG545
Description: PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
Study: NCT02543541

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive care
Description: Supportive care for the patient and caregiver will be provided by the treating oncologist.
Study: NCT01911533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extracorporeal removal of CO2 (ECCO2-R)
Description: To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
Study: NCT02866370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2.
Study: NCT01911533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No extracorporeal CO2-removal
Description: Patients are their own control group.
Study: NCT04294498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Entecavir treatment for chronic hepatitis B will be started within one week before initiation of durvalumab treatment for advanced hepatocellulcar carcinoma
Study: NCT03187288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-400945 Fumarate
Description: CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.
Study: NCT01169831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: 2 weeks of daily aerobic exercise training
Study: NCT05577897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: A separate room in Chest Diseases Clinic was used for the education of the patients in this group for a quiet environment and for the education not to be interrupted. The education of a patient lasted approximately 45 minutes. The education booklet COPD Guide on COPD management prepared in line with the literature was given to the patients by the researcher. After the content of the education was explained to the patients, 45-minute of education was given through face-to-face verbal presentation and demonstration method.
Study: NCT01169831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Cessation
Description: Stopping all exercise for 2 weeks
Study: NCT01171131

Intervention type: OTHER
Intervention: Blood/saliva sampling
Description: one-time blood sample (\~ 1 TBS) and saliva sample (\~ 1 tsp)

Intervention type: OTHER
Intervention: Blood/saliva sampling
Description: one-time blood sample (\~ 1 TBS) and saliva sample (\~ 1 tsp)

Intervention type: OTHER
Intervention: Blood/saliva sampling
Description: one-time blood sample (\~ 1 TBS) and saliva sample (\~ 1 tsp)
Study: NCT02266381

Intervention type: PROCEDURE
Group type: OTHER
Intervention: US-guided renal access
Description: Patients undergo MPCNL using only US-guided renal access.
Study: NCT02032823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
Study: NCT02266381

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fluoroscopy-guided renal access
Description: Patients undergo MPCNL using only fluoroscopy-guided renal access.
Study: NCT02032823

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
Study: NCT02266381

Intervention type: PROCEDURE
Group type: OTHER
Intervention: US combined with fluoroscopy-guided renal access
Description: Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
Study: NCT01144338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Once Weekly
Description: Subcutaneous injection, 2 mg, administered once weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection, matching volume of placebo, administered once weekly.
Study: NCT06302387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: The ADM arm involved vertical soft tissue augmentation using an acellular dermal matrix. This process included the placement of a porcine dermal collagen graft (Mucoderm®, Institut Straumann AG, Switzerland) atop the dental implant site. The graft, measuring 15x20 mm, was hydrated in a 0.5% Metronidazole solution for 20 minutes before application, then trimmed and placed to extend 10 by 5 mm beyond the implant margins in both buccal and lingual directions. The primary wound closure was achieved using double mattress suturing with 6-0 Prolene (Ethicon, USA).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft Tissue Expansion using Tenting Technique
Description: The Tenting Technique arm involved soft tissue expansion using a submerged healing abutment to promote soft tissue growth. After implant placement, 2 mm healing abutments were set on the implants. Flaps were mobilized using vertical releasing incisions, and tension-free wound closure was achieved with horizontal mattress sutures followed by suturing the incision line with interrupted sutures for primary and submerged healing. This method aimed to create a subepithelial healing space for soft tissue expansion and augmentation.
Study: NCT03430466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalmab&Tremelimumab&Fulvestrant
Description: Durvalumab and Tremelimumab once in 4 weeks Durvalumab for 13 months Tremelimumab for initial 4 months Fulvestrant : At baseline, then week 2, week 4 and after that every 4 weeks